Author of

• 12592

  +

  P3.10 - Poster Session 3 - Chemotherapy (ID 210)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12618

    +

    P3.10-026 - Outcomes of patients undergoing adjuvant platinum-vinorelbine chemotherapy for resected non-small cell lung cancer (NSCLC) (ID 1566)

    09:30 - 09:30  |  Author(s): A. Pender
    • Abstract

    Background
    Cisplatin-vinorelbine adjuvant chemotherapy significantly improves survival in resected NSCLC. We evaluated outcomes of patients receiving adjuvant chemotherapy in our institution between 2006-2011.

    Methods
    Outcomes of stage IB -IIIA NSCLC patients who received platinum-vinorelbine following radical lung surgery were collected and analysed to assess overall survival (OS), progression-free survival (PFS), and treatment intensity.

    Results
    53 patients were identified (23:30, M:F), mean age 62, and 35% were adenocarcinoma. Resected stage was 1B-3A, with one-third stage 3A. When tested, EGFR mutation prevalence was 33% (39% never smokers; 61% ever smokers). There was one death from chemotherapy toxicity. Median chemotherapy cycles given was 4. There was no difference in PFS or OS in patients having carboplatin compared with cisplatin. A significantly improved OS in patients that received ≥3 cycles of chemotherapy was observed (HR=0.25, 0.07-0.97, p=0.04). 60.4% patients had relapsed at last follow-up. Radically treatable disease on relapse was detected by surveillance imaging.

    Conclusion
    Our small dataset indicates that four cycles of adjuvant platinum-vinorelbine chemotherapy is deliverable in the real world setting, and that less than 3 chemotherapy cycles is associated with poorer outcomes.